Literature DB >> 22434096

Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma.

David E Kleiner1, David Berman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22434096      PMCID： PMC3792485          DOI： 10.1007/s10620-012-2140-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  20 in total

Review 1.  Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.

Authors:  Jeffrey Weber
Journal:  Oncologist       Date:  2007-07

Review 2.  Autoimmune hepatitis.

Authors:  Edward L Krawitt
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

Review 3.  Alcoholic hepatitis.

Authors:  Michael R Lucey; Philippe Mathurin; Timothy R Morgan
Journal:  N Engl J Med       Date:  2009-06-25       Impact factor: 91.245

Review 4.  Acute and chronic hepatitis.

Authors:  Arief A Suriawinata; Swan N Thung
Journal:  Semin Diagn Pathol       Date:  2006 Aug-Nov       Impact factor: 3.464

Review 5.  Case definition and phenotype standardization in drug-induced liver injury.

Authors:  G P Aithal; P B Watkins; R J Andrade; D Larrey; M Molokhia; H Takikawa; C M Hunt; R A Wilke; M Avigan; N Kaplowitz; E Bjornsson; A K Daly
Journal:  Clin Pharmacol Ther       Date:  2011-05-04       Impact factor: 6.875

6.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Authors:  Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé
Journal:  Lancet Oncol       Date:  2009-12-08       Impact factor: 41.316

Review 7.  Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.

Authors:  Lawrence Fong; Eric J Small
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

8.  A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.

Authors:  Jeffrey Weber; John A Thompson; Omid Hamid; David Minor; Asim Amin; Ilan Ron; Ruggero Ridolfi; Hazem Assi; Anthony Maraveyas; David Berman; Jonathan Siegel; Steven J O'Day
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

Review 9.  The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.

Authors:  Jedd D Wolchok; Yvonne Saenger
Journal:  Oncologist       Date:  2008

10.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.

Authors:  Giao Q Phan; James C Yang; Richard M Sherry; Patrick Hwu; Suzanne L Topalian; Douglas J Schwartzentruber; Nicholas P Restifo; Leah R Haworth; Claudia A Seipp; Linda J Freezer; Kathleen E Morton; Sharon A Mavroukakis; Paul H Duray; Seth M Steinberg; James P Allison; Thomas A Davis; Steven A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 12.779
View more
  41 in total

Review 1.  [The pathology of adverse events with immune checkpoint inhibitors].

Authors:  V H Koelzer; K Glatz; L Bubendorf; A Weber; A Gaspert; G Cathomas; A Lugli; A Zippelius; W Kempf; K D Mertz
Journal:  Pathologe       Date:  2017-05       Impact factor: 1.011

Review 2.  Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications.

Authors:  Lily Dara; Zhang-Xu Liu; Neil Kaplowitz
Journal:  Liver Int       Date:  2015-11-11       Impact factor: 5.828

Review 3.  Toxicities Associated With PD-1/PD-L1 Blockade.

Authors:  Daniel Y Wang; Douglas B Johnson; Elizabeth J Davis
Journal:  Cancer J       Date:  2018 Jan/Feb       Impact factor: 3.360

Review 4.  Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.

Authors:  Hiroki Nagai; Manabu Muto
Journal:  Int J Clin Oncol       Date:  2018-03-07       Impact factor: 3.402

5.  Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.

Authors:  Jaydira Del Rivero; Lisa M Cordes; Joanna Klubo-Gwiezdzinska; Ravi A Madan; Lynnette K Nieman; James L Gulley
Journal:  Oncologist       Date:  2019-10-10

Review 6.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

Authors:  J Naidoo; D B Page; B T Li; L C Connell; K Schindler; M E Lacouture; M A Postow; J D Wolchok
Journal:  Ann Oncol       Date:  2015-09-14       Impact factor: 32.976

7.  Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease.

Authors:  Agustin Castiella; Eva Zapata; M Isabel Lucena; Raúl J Andrade
Journal:  World J Hepatol       Date:  2014-04-27

8.  Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.

Authors:  Jaydira Del Rivero; Lisa M Cordes; Joanna Klubo-Gwiezdzinska; Ravi A Madan; Lynnette K Nieman; James L Gulley
Journal:  Oncologist       Date:  2019-10-10

Review 9.  Recent Advances in the Histopathology of Drug-Induced Liver Injury.

Authors:  David E Kleiner
Journal:  Surg Pathol Clin       Date:  2018-06

Review 10.  Ipilimumab and its toxicities: a multidisciplinary approach.

Authors:  Leslie A Fecher; Sanjiv S Agarwala; F Stephen Hodi; Jeffrey S Weber
Journal:  Oncologist       Date:  2013-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.